section name header

Indications

REMS

Unlabeled Uses:

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: ECG changes (T-wave abnormalities, QRS prolongation), cardiomyopathy, hypotension.

Derm: alopecia, dermatoses, photosensitivity, pigmentary changes, pruritus, skin eruptions, STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, urticaria.

EENT: corneal opacities (reversible), hearing impairment, retinopathy, tinnitus, visual disturbances.

GI: liver enzymes, abdominal cramps, anorexia, diarrhea, hepatitis, nausea, vomiting.

Hemat: AGRANULOCYTOSIS, APLASTIC ANEMIA, LEUKOPENIA, thrombocytopenia.

Neuro: agitation, anxiety, confusion, delirium, depression, extrapyramidal reactions, hallucinations, headache, insomnia, neuromyopathy, peripheral neuritis, personality changes, polyneuritis, psychosis , SEIZURES, weakness.

Interactions

Drug-Drug:

Drug-Food:

Availability

(Generic available)

Route/Dosage

see Calculator

Doses below expressed as chloroquine base: 1 mg of chloroquine base = 1.67 mg chloroquine phosphate or 1.25 mg chloroquine hydrochloride

Suppression/Prophylaxis of Malaria

Treatment of Acute Attack of Malaria

Extraintestinal Amebiasis

Rheumatoid Arthritis/Systemic Lupus Erythematosus

US Brand Names

Aralen

Action

Therapeutic Effects:

Classifications

Therapeutic Classification: antimalarials, antirheumatics (DMARDs)

Pharmacokinetics

Absorption: Well absorbed following oral administration.

Distribution: Widely distributed; high tissue concentrations achieved. Crosses the placenta, enters breast milk.

Metabolism/Excretion: 30% metabolized by the liver. Metabolite also has antiplasmodial activity; 70% excreted unchanged by the kidneys.

Half-life: 3–5 days.

Time/Action Profile

(antimalarial activity)

ROUTEONSETPEAKDURATION
POrapid1–2 hrdays–wks

Patient/Family Teaching

Pronunciation

KLOR-oh-kwin